Immatics
IMTX
Immatics (IMTX) news
Recent news
Immatics Q2 operating income EUR -67.204 million vs. IBES estimate EUR -63.5 million
AInvest Wire · Aug 18, 2026Immatics announces second quarter 2026 financial results and business update
AInvest Wire · Aug 18, 2026Immatics announces proposed $150M offering
Immatics announces proposed $150M offering Immatics, a clinical-stage biopharmaceutical company specializing in the development of immunotherapies for cancer, recently announced initial data from a Phase 1 clinical trial of its lead bispecific candidate, IMA401. The trial, which was terminated by…
AInvest Wire · Oct 10, 2024Immatics offering prices 15.9M shares at $11.00/shr.
AInvest Wire · Jan 18, 2024Immatics shares rise 4% in premarket trading on collaboration with Moderna
AInvest Wire · Sep 11, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.